ClinicalTrials.gg
CompletedNCT02696031PREVENTUpdated Apr 29, 2022Results posted

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis

A Phase 3 interventional study of Secukinumab and Placebo in Non-radiographic Spondyloarthritis, sponsored by Novartis Pharmaceuticals. Completed at 139 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
555
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Axial Spondyloarthritis with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Axial Spondyloarthritis · United States.

Enrollment
4th of 31
555 · median 200
Started
2016
with 3 others
Phase 3
13 of 34
none open now
Registered
9th of 34
by date
Lead sponsor
2 of 34
Novartis Pharmaceuticals

Among the 34 studies in Axial Spondyloarthritis with a site in United States, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2016, is one of 13 in phase 3, and was the 9th registered.

Axial Spondyloarthritis

186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

7 of the 34 studies in Axial Spondyloarthritis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Axial Spondyloarthritis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study was to demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with nr-axSpA at Week 16 as well as Week 52 and long term efficacy and safety up to Week 104 (core phase) followed by an optional extension phase consisting of a 16-week randomized dose escalation treatment period and a continuous treatment period for up to Week 208

Read the detailed description

Patients were randomized to one of three treatment groups (1:1:1) in the core phase:

  • Secukinumab 150 mg Load: secukinumab 150 mg (1 mL, 150 mg/mL) s.c. pre-filled syringe (PFS) at baseline, Weeks 1, 2, and 3, followed by administration every four weeks starting at Week 4
  • Secukinumab 150 mg No Load: secukinumab 150 mg (1 mL, 150 mg/mL) s.c. PFS at baseline, placebo at Weeks 1, 2, and 3, followed by secukinumab 150 mg PFS administration every four weeks starting at Week 4
  • Placebo: placebo (1 mL) s.c. PFS at baseline, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4.

All patients received secukinumab 150 mg as open-label treatment from Week 52 up to Week 100, unless they had discontinued study treatment.

At Week 104, all patients who finished the core phase according to the protocol were asked to continue in an optional, exploratory extension phase. Patients who achieved ASAS20 response at Week 104 (Core Phase Responders) were randomized to the following treatment groups (blinded) in the extension phase:

  • Core Phase Responder 150 mg: secukinumab 150 mg (1 mL, 150 mg/mL) s.c. PFS and placebo (1 mL) s.c. PFS every four weeks;
  • Core Phase Responder 300 mg: 2 injections with secukinumab 150 mg (1 mL, 150 mg/mL) s.c. PFS every four weeks.

Core Phase Non-Responders (not achieving ASAS20 at Week 104) were escalated to secukinumab 300 mg in an open-label manner.

  • Core Phase Non-Responder 300 mg: 2 injections with secukinumab 150 mg (1 mL, 150 mg/mL) s.c. PFS every four weeks open-label.

Starting from Week 156 onward, a patient could switch to secukinumab 300 mg open-label based on the clinical judgment of disease activity by the investigator.

03

Conditions studied

  • Non-radiographic Spondyloarthritis

Keywords

  • non-radiographic spondyloarthritis
  • axial spondyloarthritis
  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant, non-nursing female patients at least 18 years of age
  • Diagnosis of axial spondyloarthritis according to Ankylosing SpondyloArthritis International Society (ASAS) axial spondyloarthritis criteria
  • objective signs of inflammation (magnetic resonance imaging (MRI) or abnormal C-reactive protein)
  • active axial spondyloarthritis as assessed by total Bath Ankylosing Spondylitis Disease Activity Index >=4 cm
  • Spinal pain as measured by Bath Ankylosing Spondylitis Disease Activity Index question #2 ≥ 4 cm (0-10 cm) at baseline
  • Total back pain as measured by Visual Analogue scale ≥ 40 mm (0-100 mm) at baseline
  • Patients should have been on at least 2 different non-steroidal anti-inflammatory drugs with an inadequate response
  • Patients who have been on a Tumor Necrosis Factor (TNF) α inhibitor (not more than one) must have experienced an inadequate response

Exclusion criteria

Exclusion Criteria:

  • Patients with radiographic evidence for sacroiliitis, grade ≥ 2 bilaterally or grade ≥ 3 unilaterally
  • Inability or unwillingness to undergo MRI
  • Chest X-ray or MRI with evidence of ongoing infectious or malignant process
  • Patients taking high potency opioid analgesics
  • Previous exposure to secukinumab or any other biologic drug directly targeting interleukin-17 (IL-17) or IL-17 receptor
  • Pregnant or nursing (lactating) women
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
555 participants (actual)

Study arms

  • Experimental
    Secukinumab, 150 mg Load (Core phase)

    Secukinumab 150 mg s.c., pre-filled syringe (PFS) at baseline, Weeks 1, 2, and 3, followed by administration every four weeks starting at Week 4, Load, Core phase

    Drug: Secukinumab

  • Experimental
    Secukinumab, 150 mg No Load (Core phase)

    Secukinumab 150 mg s.c. PFS at baseline, placebo at Weeks 1, 2, and 3, followed by secukinumab 150 mg PFS administration every four weeks starting at Week 4, No Load, Core phase

    Drug: Secukinumab

  • Placebo comparator
    Placebo (Core phase)

    Placebo s.c., PFS at baseline, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4, Core phase

    Drug: Placebo

  • Experimental
    Core Phase Responder 150 mg (Extension phase)

    Core Phase Responder 150 mg blinded: secukinumab 150 mg s.c. PFS and placebo (1 mL) s.c. PFS every four weeks, in the Extension phase

    Drug: Secukinumab · Drug: Placebo

  • Experimental
    Core Phase Responder 300 mg (Extension phase)

    Core Phase Responder 300 mg blinded: 2 injections with secukinumab 150 mg s.c. PFS every four weeks, in the Extension phase

    Drug: Secukinumab

  • Experimental
    Core Phase Non-Responder 300 mg (Extension phase)

    Core Phase Non-Responder 300 mg: 2 injections with secukinumab 150 mg s.c. PFS every four weeks open-label, in the Extension phase

    Drug: Secukinumab

Interventions

  • Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly

    Also known as: AIN457

  • DrugPlacebo

    Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly

    Also known as: AIN457

06

What researchers measure

Primary outcomes

  1. The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response at Week 16

    Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.

    Time frame: Week 16

  2. The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 52

    Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.

    Time frame: Week 52

Secondary outcomes

  1. The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response

    Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.

    Time frame: Week 16 and week 52

  2. The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 20 Response

    Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS 20 response is defined as an improvement of ≥20% and ≥1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain. A higher score on the VAS signifies higher severity.

    Time frame: Week 16

  3. The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response

    Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains. A higher score on the VAS signifies higher severity.

    Time frame: Week 16

  4. The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society Partial Remission (ASAS PR)

    Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). The ASAS partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10. A higher score on the VAS signifies higher severity.

    Time frame: Week 16

  5. Change in Bath Ankylosing Spondylitis Functional Index (BASFI)

    The Bath Ankylosing Spondylitis Functional Index (BASFI) is a set of 10 questions designed to determine the degree of functional limitation in those subjects with AS. The ten questions were chosen with a major input from subjects with AS. The first 8 questions consider activities related to functional anatomy. The final 2 questions assess the subjects' ability to cope with everyday life. A 100 mm visual analog scale (VAS) is used to answer the questions. The mean of the ten questions gives the BASFI score - a value between 0 and 10. (0 being no problem and 10 being the worst problem, captured as a continuous visual analog scale (VAS)). A higher score on the VAS signifies higher severity.

    Time frame: Baseline and Week 16

  6. The Number and Percentage of Patients to Achieve a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response

    The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS. The BASDAI 50 is defined as an improvement of at least 50% in the BASDAI compared to baseline. A higher score on the VAS signifies higher severity.

    Time frame: Week 16 and 52

  7. Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

    The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated assessment tool using 1 through 10 scales (1 indicating "no problem" and 10 indicating " worst problem"), to characterize six clinical domains (fatigue, spinal pain, joint pain/selling, localized tenderness, morning stiffness duration, morning stiffness severity) pertaining to five major symptoms of Ankylosing Spondylitis (AS). The computed final BASDAI score is a value between 0 and 10 with a higher score indicating worse disease. A higher score on the VAS signifies higher severity.

    Time frame: Baseline and Week 16

  8. Change in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 16

    The Ankylosing Spondylitis Quality of Life scores (ASQoL) is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower score indicate better quality of life. Items include an assessment of mobility/energy, self-care and mood/emotion. The recall period is "at the moment," and the measure requires approximately 6 minutes to complete.

    Time frame: Baseline and Week 16

  9. Change in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 52

    The Ankylosing Spondylitis Quality of Life scores (ASQoL) is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower score indicate better quality of life. Items include an assessment of mobility/energy, self-care and mood/emotion. The recall period is "at the moment," and the measure requires approximately 6 minutes to complete. Summary statistics are presented for participants (n) without intercurrent events.

    Time frame: Baseline and Week 52

  10. The Number and Percentage of Patients Who Achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Inactive Disease

    Ankylosing Spondylitis Disease Activity Score (ASDAS) - C-reactive protein (CRP) inactive disease criteria are defined as a value below 1.3. Higher score indicates worse symptoms. The formula is: ASDAS-CRP = 0.121 x total back pain + 0.110 x patient global + 0.073 x peripheral pain/swelling + 0.058 x duration of morning stiffness + 0.579 x ln(hsCRP +1)

    Time frame: Week 52

  11. Change in High Sensitivity C-reactive Protein

    High sensitivity C-reactive protein is measured as a marker of inflammation from blood samples during the study.

    Time frame: Baseline and Week 16

  12. Change in Short Form-36 Physical Component Summary (SF-36 PCS)

    The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. Two overall summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS) also can be computed. The eight domains are based on a scale from 0-100 while PCS and MCS are norm-based scores with a mean of 50 and a standard deviation of 10. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.

    Time frame: Baseline and Week 16

  13. Change in Sacroiliac Joint Edema - Week 16

    Magnetic Resonance Images (MRI) of the Sacroiliac Joint (SIJ) were assessed for the presence and severity of SIJ bone marrow edema according to the Berlin Active Inflammatory Lesions Scoring with a maximum score of 24.

    Time frame: Baseline and Week 16

  14. Change in Sacroiliac Joint Edema - Week 52

    Magnetic Resonance Images (MRI) of the Sacroiliac Joint (SIJ) were assessed for the presence and severity of SIJ bone marrow edema according to the Berlin Active Inflammatory Lesions Scoring with a maximum score of 24.

    Time frame: Baseline and Week 52

07

Results

Posted Aug 7, 2020

Participant flow

A total of 1583 patients were screened for this study, of which 555 patients (35.1%) were randomized. Overall, 1028 patients (64.9%) discontinued prior to screening phase completion, most due to screen failure (1000 patients, 63.2%).

Up to Week 24
Participant flow — Up to Week 24
MilestoneSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core PhaseAIN457 150 mg Extension PhaseAIN457 300 mg Extension PhaseAIN457 300 mg Open Label Extension Phase
Started185184186000
Completed175177175000
Not completed10711000
Withdrew: Adverse event242000
Withdrew: Lack of efficacy212000
Withdrew: Lost to follow-up011000
Withdrew: Physician decision101000
Withdrew: Protocol violation100000
Withdrew: Withdrawal by subject415000
Up to Week 52
Participant flow — Up to Week 52
MilestoneSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core PhaseAIN457 150 mg Extension PhaseAIN457 300 mg Extension PhaseAIN457 300 mg Open Label Extension Phase
Started185184186000
Completed156165160000
Not completed291926000
Withdrew: Adverse event453000
Withdrew: Lack of efficacy10711000
Withdrew: Lost to follow-up111000
Withdrew: Physician decision112000
Withdrew: Pregnancy020000
Withdrew: Protocol violation100000
Withdrew: Withdrawal by subject1239000
Up to Week 104
Participant flow — Up to Week 104
MilestoneSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core PhaseAIN457 150 mg Extension PhaseAIN457 300 mg Extension PhaseAIN457 300 mg Open Label Extension Phase
Started185184186000
Completed146143149000
Not completed394137000
Withdrew: Pregnancy021000
Withdrew: Withdrawal by subject151016000
Withdrew: Protocol violation100000
Withdrew: Physician decision123000
Withdrew: Lost to follow-up231000
Withdrew: Lack of efficacy131211000
Withdrew: Adverse event7115000
Withdrew: Pt completed wk 52. withdrawal by subject at wk 52.010000
Extension Phase From wk 104 to wk 208
Participant flow — Extension Phase From wk 104 to wk 208
MilestoneSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core PhaseAIN457 150 mg Extension PhaseAIN457 300 mg Extension PhaseAIN457 300 mg Open Label Extension Phase
Started00014714778
Completed00013713272
Not completed00010156
Withdrew: Withdrawal by subject000682
Withdrew: Physician decision000110
Withdrew: Non-compliance with study treatment000100
Withdrew: Lost to follow-up000010
Withdrew: Lack of efficacy000113
Withdrew: Adverse event000141

Outcome measures

PrimaryThe Number and Percentage of TNF Naive Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response at Week 16

Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response at Week 16
ParticipantsSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of Spondylo Arthritis International Society (ASAS) 40 Response at Week 16687050
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0197 (unadjusted p-value) · Odds ratio (or): 1.72 · 95% CI 1.09 to 2.70
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0146 (unadjusted p-value) · Odds ratio (or): 1.76 · 95% CI 1.12 to 2.76
PrimaryThe Number and Percentage of TNF Naive Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 52

Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.

Time frame:
Week 52
Reported as:
Count of participants · Participants
The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 52
ParticipantsSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
The Number and Percentage of TNF Naive Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response at Week 52586634
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0017 (unadjusted p-value) · Odds ratio (or): 2.21 · 95% CI 1.35 to 3.63
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = <.0001 (unadjusted p-value) · Odds ratio (or): 2.67 · 95% CI 1.64 to 4.36
SecondaryThe Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response

Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain. A higher score on the VAS signifies higher severity.

Time frame:
Week 16 and week 52
Reported as:
Count of participants · Participants
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 40 Response
ParticipantsSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
week 16747552
week 52627036
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0108 (unadjusted p-value) · Odds ratio (or): 1.77 · 95% CI 1.14 to 2.74
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0087 (unadjusted p-value) · Odds ratio (or): 1.80 · 95% CI 1.16 to 2.78
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · Regression, Linear · p = 0.0016 (unadjusted p-value) · Odds ratio (or): 2.16 · 95% CI 1.34 to 3.49
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · Regression, Linear · p = <.0001 (unadjusted p-value) · Median difference (net): 2.61 · 95% CI 1.62 to 4.19
SecondaryThe Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 20 Response

Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). ASAS 20 response is defined as an improvement of ≥20% and ≥1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥20% and ≥1 unit on a scale of 10 in the remaining domain. A higher score on the VAS signifies higher severity.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 20 Response
ParticipantsSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 20 Response10510785
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0260 (unadjusted p-value) · Odds ratio (or): 1.60 · 95% CI 1.06 to 2.43
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0149 (unadjusted p-value) · Odds ratio (or): 1.68 · 95% CI 1.11 to 2.54
SecondaryThe Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response

Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains. A higher score on the VAS signifies higher severity.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response
ParticipantsSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response746644
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0005 (unadjusted p-value) · Odds ratio (or): 2.26 · 95% CI 1.43 to 3.58
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0094 (unadjusted p-value) · Odds ratio (or): 1.85 · 95% CI 1.16 to 2.94
SecondaryThe Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society Partial Remission (ASAS PR)

Assessment of SpondyloArthritis International Society criteria (ASAS) consist of 6 domains (4 main and 2 additional assessment domains): 1. Patient's global assessment measured on a visual analog scale (VAS); 2. Patient's assessment of back pain, measured on a VAS; 3. Function represented by Bath Ankylosing Spondylitis Functional Index (BASFI) average of 10 questions as measured by VAS; 4. Inflammation represented by mean duration and severity of morning stiffness, on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as measured by VAS; 5. Spinal mobility represented by the Bath Ankylosing Spondylitis Metrology Index (BASMI) lateral spinal flexion assessment; 6. C-reactive protein (acute phase reactant). The ASAS partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10. A higher score on the VAS signifies higher severity.

Time frame:
Week 16
Reported as:
Count of participants · Participants
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society Partial Remission (ASAS PR)
ParticipantsSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
The Number and Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society Partial Remission (ASAS PR)403913
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = <.0001 (unadjusted p-value) · Odds ratio (or): 3.80 · 95% CI 1.95 to 7.39
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0001 (unadjusted p-value) · Odds ratio (or): 3.64 · 95% CI 1.87 to 7.10
SecondaryChange in Bath Ankylosing Spondylitis Functional Index (BASFI)

The Bath Ankylosing Spondylitis Functional Index (BASFI) is a set of 10 questions designed to determine the degree of functional limitation in those subjects with AS. The ten questions were chosen with a major input from subjects with AS. The first 8 questions consider activities related to functional anatomy. The final 2 questions assess the subjects' ability to cope with everyday life. A 100 mm visual analog scale (VAS) is used to answer the questions. The mean of the ten questions gives the BASFI score - a value between 0 and 10. (0 being no problem and 10 being the worst problem, captured as a continuous visual analog scale (VAS)). A higher score on the VAS signifies higher severity.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Index
Change in Bath Ankylosing Spondylitis Functional Index (BASFI)
IndexSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
Change in Bath Ankylosing Spondylitis Functional Index (BASFI)-1.75 ± 0.202-1.64 ± 0.204-1.01 ± 0.206
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · MMRM · p = 0.0041 (unadjusted p-value) · Ls mean: -0.75 · 95% CI -1.26 to -0.24
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · MMRM · p = 0.0143 (unadjusted p-value) · Ls mean: -0.64 · 95% CI -1.15 to -0.13
SecondaryThe Number and Percentage of Patients to Achieve a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response

The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) consists of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which is used to answer 6 questions pertaining to the 5 major symptoms of AS. The BASDAI 50 is defined as an improvement of at least 50% in the BASDAI compared to baseline. A higher score on the VAS signifies higher severity.

Time frame:
Week 16 and 52
Reported as:
Count of participants · Participants
The Number and Percentage of Patients to Achieve a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response
ParticipantsSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
week 16696939
week 52576537
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0001 (unadjusted p-value) · Odds ratio (or): 2.53 · 95% CI 1.58 to 4.07
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0002 (unadjusted p-value) · Odds ratio (or): 2.43 · 95% CI 1.51 to 3.89
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0056 (unadjusted p-value) · Odds ratio (or): 1.99 · 95% CI 1.22 to 3.24
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0005 (unadjusted p-value) · Odds ratio (or): 2.34 · 95% CI 1.45 to 3.78
SecondaryChange in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a validated assessment tool using 1 through 10 scales (1 indicating "no problem" and 10 indicating " worst problem"), to characterize six clinical domains (fatigue, spinal pain, joint pain/selling, localized tenderness, morning stiffness duration, morning stiffness severity) pertaining to five major symptoms of Ankylosing Spondylitis (AS). The computed final BASDAI score is a value between 0 and 10 with a higher score indicating worse disease. A higher score on the VAS signifies higher severity.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · scores on a scale
Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
scores on a scaleSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)-2.35 ± 0.201-2.43 ± 0.203-1.46 ± 0.205
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · mixed model repeated measures (MMRM) · p = 0.0006 (unadjusted p-value) · Ls mean of treatment difference: -0.89 · 95% CI -1.39 to -0.38
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · mixed model repeated measures (MMRM) · p = 0.0002 (unadjusted p-value) · Ls mean of treatment difference: -0.97 · 95% CI -1.47 to -0.47
SecondaryChange in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 16

The Ankylosing Spondylitis Quality of Life scores (ASQoL) is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower score indicate better quality of life. Items include an assessment of mobility/energy, self-care and mood/emotion. The recall period is "at the moment," and the measure requires approximately 6 minutes to complete.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Scores on a scale
Change in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 16
Scores on a scaleSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
Change in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 16-3.45 ± 0.408-3.62 ± 0.414-1.84 ± 0.421
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · MMRM · p = 0.0008 (unadjusted p-value) · Ls mean: -1.61 · 95% CI -2.54 to -0.67
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · MMRM · p = 0.0002 (unadjusted p-value) · Ls mean: -1.78 · 95% CI -2.72 to -0.84
SecondaryChange in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 52

The Ankylosing Spondylitis Quality of Life scores (ASQoL) is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity). As such, lower score indicate better quality of life. Items include an assessment of mobility/energy, self-care and mood/emotion. The recall period is "at the moment," and the measure requires approximately 6 minutes to complete. Summary statistics are presented for participants (n) without intercurrent events.

Time frame:
Baseline and Week 52
Reported as:
Mean · Scores on a scale
Change in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 52
Scores on a scaleSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
Change in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 52-7.1 ± 4.77-7.6 ± 5.38-6.4 ± 4.64
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · Wilcoxon (Mann-Whitney) · p = 0.0012 (unadjusted p-value)The endpoint was analyzed by composite estimand strategy. Extreme unfavorable value is assigned for patients with treatment escape or missing data.
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · Wilcoxon (Mann-Whitney) · p = <.0001 (unadjusted p-value)The endpoint was analyzed by composite estimand strategy. Extreme unfavorable value is assigned for patients with treatment escape or missing data.
SecondaryThe Number and Percentage of Patients Who Achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Inactive Disease

Ankylosing Spondylitis Disease Activity Score (ASDAS) - C-reactive protein (CRP) inactive disease criteria are defined as a value below 1.3. Higher score indicates worse symptoms. The formula is: ASDAS-CRP = 0.121 x total back pain + 0.110 x patient global + 0.073 x peripheral pain/swelling + 0.058 x duration of morning stiffness + 0.579 x ln(hsCRP +1)

Time frame:
Week 52
Reported as:
Count of participants · Participants
The Number and Percentage of Patients Who Achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Inactive Disease
ParticipantsSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
The Number and Percentage of Patients Who Achieved an Ankylosing Spondylitis Disease Activity Score (ASDAS)-C-Reactive Protein (CRP) Inactive Disease294419
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0577 (unadjusted p-value) · Odds ratio (or): 1.84 · 95% CI 0.98 to 3.45
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · Regression, Logistic · p = 0.0003 (unadjusted p-value) · Odds ratio (or): 2.99 · 95% CI 1.65 to 5.41
SecondaryChange in High Sensitivity C-reactive Protein

High sensitivity C-reactive protein is measured as a marker of inflammation from blood samples during the study.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · ratio
Change in High Sensitivity C-reactive Protein
ratioSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
Change in High Sensitivity C-reactive Protein0.64 ± 1.0780.64 ± 1.0790.91 ± 1.080
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · MMRM · p = 0.0002 (unadjusted p-value) · Relative treatment effect: 0.70 · 95% CI 0.58 to 0.84
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · MMRM · p = 0.0002 (unadjusted p-value) · Relative treatment effect: 0.70 · 95% CI 0.58 to 0.84
SecondaryChange in Short Form-36 Physical Component Summary (SF-36 PCS)

The Short Form-36 Physical Component Summary (SF-36 PCS) is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consists of eight subscales (domains) that can be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. Two overall summary scores, the Physical Component Summary (PCS) and the Mental Component Summary (MCS) also can be computed. The eight domains are based on a scale from 0-100 while PCS and MCS are norm-based scores with a mean of 50 and a standard deviation of 10. Higher scores indicate a higher level of functioning. A positive change from baseline score indicates an improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Scores on a Scale
Change in Short Form-36 Physical Component Summary (SF-36 PCS)
Scores on a ScaleSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
Change in Short Form-36 Physical Component Summary (SF-36 PCS)5.71 ± 0.6835.57 ± 0.6942.93 ± 0.705
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · ANCOVA · p = 0.0006 (unadjusted p-value) · Ls mean of treatment difference: 2.77 · 95% CI 1.20 to 4.34
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · ANCOVA · p = 0.0011 (unadjusted p-value) · Ls mean of treatment difference: 2.64 · 95% CI 1.06 to 4.22
SecondaryChange in Sacroiliac Joint Edema - Week 16

Magnetic Resonance Images (MRI) of the Sacroiliac Joint (SIJ) were assessed for the presence and severity of SIJ bone marrow edema according to the Berlin Active Inflammatory Lesions Scoring with a maximum score of 24.

Time frame:
Baseline and Week 16
Reported as:
Mean · Scores on a Scale
Change in Sacroiliac Joint Edema - Week 16
Scores on a ScaleSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
Change in Sacroiliac Joint Edema - Week 16-1.68 ± 0.24-1.03 ± 0.18-0.39 ± 0.15
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · ANCOVA · p = <0.0001 (unadjusted p-value)
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · ANCOVA · p = <0.0001 (unadjusted p-value)
SecondaryChange in Sacroiliac Joint Edema - Week 52

Magnetic Resonance Images (MRI) of the Sacroiliac Joint (SIJ) were assessed for the presence and severity of SIJ bone marrow edema according to the Berlin Active Inflammatory Lesions Scoring with a maximum score of 24.

Time frame:
Baseline and Week 52
Reported as:
Mean · Scores on a scale
Change in Sacroiliac Joint Edema - Week 52
Scores on a scaleSecukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core Phase
Change in Sacroiliac Joint Edema - Week 52-2.9 ± 4.54-1.9 ± 3.40-0.1 ± 1.97
Statistical analysis
  • Secukinumab, Load, Core Phase vs Placebo, Core Phase · Wilcoxon (Mann-Whitney) · p = <.0001 (unadjusted p-value)The endpoint was analyzed by composite estimand strategy. Extreme unfavorable value is assigned for patients with treatment escape or missing data.
  • Secukinumab, No Load, Core Phase vs Placebo, Core Phase · Wilcoxon (Mann-Whitney) · p = <.0001 (unadjusted p-value)The endpoint was analyzed by composite estimand strategy. Extreme unfavorable value is assigned for patients with treatment escape or missing data.

Adverse events

Collected over Adverse events are reported from first dose of study treatment until end of study treatment plus 12 wks post-treatment, up to a maximum timeframe of 1520 days (approx. 4.2 years). Safety results summarize long term data for all patients for the entire period of their study participation, which, for the majority of pts, combines the core phase and the extension phase (not all pts participated in the extension). The table is presented by dose group, AIN457 150 mg and AIN457 300 mg and placebo.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Any AIN457 150 mg, in Core Phase and Extension Phase0/543 (0%)48/543 (8.8%)320/543 (58.9%)
Any AIN457 300 mg in Extension Phase0/254 (0%)11/254 (4.3%)74/254 (29.1%)
Any AIN457, In Core Phase and Extension Phase0/543 (0%)58/543 (10.7%)335/543 (61.7%)
Placebo, Core Phase0/186 (0%)8/186 (4.3%)67/186 (36%)
Most frequent serious events
Showing 10 of 83
Most frequent serious events
EventAny AIN457 150 mg, in Core Phase and Extension PhaseAny AIN457 300 mg in Extension PhaseAny AIN457, In Core Phase and Extension PhasePlacebo, Core Phase
Crohn's diseaseGastrointestinal disorders2/5431/2543/5430/186
TonsillitisInfections and infestations3/5430/2543/5430/186
ArthritisMusculoskeletal and connective tissue disorders3/5430/2543/5430/186
Acute coronary syndromeCardiac disorders0/5430/2540/5431/186
Myocardial infarctionCardiac disorders0/5430/2540/5431/186
PyrexiaGeneral disorders0/5430/2540/5431/186
Viral tracheitisInfections and infestations0/5430/2540/5431/186
Clavicle fractureInjury, poisoning and procedural complications0/5430/2540/5431/186
ArthralgiaMusculoskeletal and connective tissue disorders0/5430/2540/5431/186
Back painMusculoskeletal and connective tissue disorders1/5430/2541/5431/186
Most frequent other events
Showing 10 of 11
Most frequent other events
EventAny AIN457 150 mg, in Core Phase and Extension PhaseAny AIN457 300 mg in Extension PhaseAny AIN457, In Core Phase and Extension PhasePlacebo, Core Phase
NasopharyngitisInfections and infestations137/54333/254146/54332/186
Upper respiratory tract infectionInfections and infestations65/54316/25477/54313/186
HeadacheNervous system disorders61/5437/25465/5439/186
DiarrhoeaGastrointestinal disorders55/5436/25461/54310/186
ArthralgiaMusculoskeletal and connective tissue disorders43/5436/25448/5439/186
Urinary tract infectionInfections and infestations38/5439/25442/5434/186
Back painMusculoskeletal and connective tissue disorders36/5433/25438/5433/186
SinusitisInfections and infestations30/5435/25434/5433/186
HypertensionVascular disorders29/5435/25434/5433/186
PharyngitisInfections and infestations27/5435/25431/5431/186

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Secukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core PhaseTotal
<=18 years0000
Between 18 and 65 years183180183546
>=65 years2439
Age, Continuous
Age, Continuous(Years)Secukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core PhaseTotal
Mean39.1 ± 11.4539.8 ± 11.6839.3 ± 11.4739.4 ± 11.52
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core PhaseTotal
Female10510095300
Male808491255
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Secukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core PhaseTotal
Hispanic or Latino98724
Not Hispanic or Latino165162161488
Unknown or Not Reported11141843
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Secukinumab, Load, Core PhaseSecukinumab, No Load, Core PhasePlacebo, Core PhaseTotal
American Indian or Alaska Native0202
Asian481123
Black or African American0213
White176165167508
Other57719
08

Study locations

139 sites
  • Novartis Investigative Site
    Birmingham, Alabama 35205, United States
  • Novartis Investigative Site
    Beverly Hills, California 90211, United States
  • Novartis Investigative Site
    Fullerton, California 92835, United States
  • Novartis Investigative Site
    Denver, Colorado 80230, United States
  • Novartis Investigative Site
    Gainesville, Florida 32608, United States
  • Novartis Investigative Site
    Idaho Falls, Idaho 83404, United States
  • Novartis Investigative Site
    Bowling Green, Kentucky 42101, United States
  • Novartis Investigative Site
    Lansing, Michigan 48910, United States
  • Novartis Investigative Site
    Great Falls, Montana 59405, United States
  • Novartis Investigative Site
    Albany, New York 12206, United States
  • Novartis Investigative Site
    Potsdam, New York 13676, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28204, United States
  • Novartis Investigative Site
    Oklahoma City, Oklahoma 73102, United States
  • Novartis Investigative Site
    Portland, Oregon 97239, United States
  • Novartis Investigative Site
    Duncansville, Pennsylvania 16635, United States
  • Novartis Investigative Site
    Charleston, South Carolina 29460, United States
  • Novartis Investigative Site
    Leander, Texas 78641, United States
  • Novartis Investigative Site
    Mesquite, Texas 75150, United States
  • Novartis Investigative Site
    Coffs Harbour, New South Wales 2450, Australia
  • Novartis Investigative Site
    Maroochydore, Queensland 4558, Australia
  • Novartis Investigative Site
    Hobart, Tasmania 7000, Australia
  • Novartis Investigative Site
    Malvern East, Victoria 3145, Australia
  • Novartis Investigative Site
    Woolloongabba, QLD 4102, Australia
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Vienna, A-1060, Austria
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Genk, 3600, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Sofia, 1606, Bulgaria
  • Novartis Investigative Site
    Sofia, 1784, Bulgaria
  • Novartis Investigative Site
    Praha 11, Czech Republic 148 00, Czechia
  • Novartis Investigative Site
    Praha 2, Czech Republic 128 50, Czechia
  • Novartis Investigative Site
    Praha 5, Czech Republic 150 06, Czechia
  • Novartis Investigative Site
    Brno-Zidonice, CZE 61500, Czechia
  • Novartis Investigative Site
    Brno, CZ 625 00, Czechia
  • Novartis Investigative Site
    Uherske Hradiste, 686 01, Czechia
  • Novartis Investigative Site
    Limoges cedex, Haute Vienne 87000, France
  • Novartis Investigative Site
    Bordeaux Cedex, 33076, France
  • Novartis Investigative Site
    Boulogne Billancourt, 92104, France
  • Novartis Investigative Site
    Chambray les Tours, 37170, France
  • Novartis Investigative Site
    Monaco, 98000, France
  • Novartis Investigative Site
    Paris Cedex 14, 75679, France
  • Novartis Investigative Site
    Poitiers, 86021, France
  • Novartis Investigative Site
    Rouen Cedex, 76031, France
  • Novartis Investigative Site
    Hannover, Niedersachsen 30159, Germany
  • Novartis Investigative Site
    Berlin, 13125, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Cottbus, 03042, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Hamburg, 22143, Germany
  • Novartis Investigative Site
    Hamburg, 22415, Germany
  • Novartis Investigative Site
    Hamburg, 22767, Germany
  • Novartis Investigative Site
    Herne, 44649, Germany
  • Novartis Investigative Site
    Magdeburg, 39110, Germany
  • Novartis Investigative Site
    Potsdam, 14469, Germany
  • Novartis Investigative Site
    Budapest, 1027, Hungary
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Eger, 3300, Hungary
  • Novartis Investigative Site
    Szeged, 6720, Hungary
  • Novartis Investigative Site
    Szekesfehervar, 8000, Hungary
  • Novartis Investigative Site
    Veszprem, 8200, Hungary
  • Novartis Investigative Site
    Haifa, 3109601, Israel
  • Novartis Investigative Site
    Kfar Saba, 4428164, Israel
  • Novartis Investigative Site
    Ramat Gan, 52621, Israel
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
  • Novartis Investigative Site
    Verona, VR 37126, Italy
  • Novartis Investigative Site
    Bologna, 40138, Italy
  • Novartis Investigative Site
    Novara, 28100, Italy
  • Novartis Investigative Site
    Padova, 35128, Italy
  • Novartis Investigative Site
    Pisa, 56126, Italy
  • Novartis Investigative Site
    Kita-gun, Kagawa 761-0793, Japan
  • Novartis Investigative Site
    Kawachinagano, Osaka 586-8521, Japan
  • Novartis Investigative Site
    Bunkyo ku, Tokyo 113-8431, Japan
  • Novartis Investigative Site
    Chuo ku, Tokyo 104-8560, Japan
  • Novartis Investigative Site
    Meguro, Tokyo 153-8515, Japan
  • Novartis Investigative Site
    Shinjuku ku, Tokyo 162 8666, Japan
  • Novartis Investigative Site
    Seoul, 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06351, Korea, Republic of
  • Novartis Investigative Site
    Torreon, Coahuila 27000, Mexico
  • Novartis Investigative Site
    Metepec, Estado De Mexico 52140, Mexico
  • Novartis Investigative Site
    Guadalajara, Jalisco 44160, Mexico
  • Novartis Investigative Site
    Culiacan, MEX 80000, Mexico
  • Novartis Investigative Site
    Amsterdam, 1105 AZ, Netherlands
  • Novartis Investigative Site
    Groningen, 9713 GZ, Netherlands
  • Novartis Investigative Site
    Maastricht, 6229 HX, Netherlands
  • Novartis Investigative Site
    Kongsvinger, 2212, Norway
  • Novartis Investigative Site
    Moss, 1538, Norway
  • Novartis Investigative Site
    Krakow, 30-510, Poland
  • Novartis Investigative Site
    Poznan, 60-218, Poland
  • Novartis Investigative Site
    Poznan, 61 113, Poland
  • Novartis Investigative Site
    Warszawa, 02 118, Poland
  • Novartis Investigative Site
    Warszawa, 04 305, Poland
  • Novartis Investigative Site
    Wroclaw, 53-224, Poland
  • Novartis Investigative Site
    Almada, 2801 951, Portugal
  • Novartis Investigative Site
    Braga, 4710243, Portugal
  • Novartis Investigative Site
    Lisboa, 1050-034, Portugal
  • Novartis Investigative Site
    Lisboa, 1649-035, Portugal

Showing the first 100 of 139 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Merola JF, McInnes IB, Deodhar AA, Dey AK, Adamstein NH, Quebe-Fehling E, Aassi M, Peine M, Mehta NN. Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications. Rheumatol Ther. 2022 Jun;9(3):935-955. doi: 10.1007/s40744-022-00434-z. Epub 2022 Mar 19. PubMed 35305260 ↗
  • Braun J, Blanco R, Marzo-Ortega H, Gensler LS, van den Bosch F, Hall S, Kameda H, Poddubnyy D, van de Sande M, Wiksten AS, Porter BO, Shete A, Richards HB, Haemmerle S, Deodhar A. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Res Ther. 2021 Sep 4;23(1):231. doi: 10.1186/s13075-021-02613-9. PubMed 34481517 ↗
  • Deodhar A, Blanco R, Dokoupilova E, Hall S, Kameda H, Kivitz AJ, Poddubnyy D, van de Sande M, Wiksten AS, Porter BO, Richards HB, Haemmerle S, Braun J. Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study. Arthritis Rheumatol. 2021 Jan;73(1):110-120. doi: 10.1002/art.41477. Epub 2020 Nov 24. PubMed 32770640 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Jul 2019, 38 months.

Results were first posted in Aug 2020, 1 year 1 month after primary completion.

Of 20 phase 3 interventional studies under Axial Spondyloarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 39. This study's 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2015
First posted
Mar 2, 2016
StartActual
Apr 29, 2016
Primary completionActual
Jul 1, 2019
CompletionActual
Mar 11, 2021
Results first posted
Aug 7, 2020
Last update
Apr 29, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02696031
Responsible party
Sponsor
First posted
Mar 2, 2016
Start date
Apr 29, 2016
Primary completion
Jul 1, 2019
Completion
Mar 11, 2021
Results posted
Aug 7, 2020
Last update
Apr 29, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion